Star Observer19m
Douches, Long-Acting Jabs, Implants – All The New HIV Prevention Products Coming Our Way
From an anal PrEP douche to the first women-controlled HIV prevention product, here's all the new HIV prevention products ...
Business Wire1d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...
Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
2minutemedicine.com5d
Twice-yearly lenacapavir prevents HIV more effectively than daily F/TDF or F/TAF
In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...
BMJ6d
Lenacapavir: a giant step forward in HIV prevention—but a missed opportunity for achieving equity and access
This year has seen a double dose of optimism in the field of HIV prevention. First, on 20 June 2024, came the results of the Purpose-1 trial in South Africa and Uganda.1 This randomised controlled ...
The American Journal of Managed Care10d
Lenacapavir Highly Effective in Preventing HIV
New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex ...
News246d
Efficacy of 6-monthly HIV prevention jab confirmed in second major study
The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...
Managed Healthcare Executive6d
PrEP Overview in Light of Lenacapavir Licensing Agreements
Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...
The Nation Newspaper13d
Lenacapavir injection shows 96% efficacy in HIV prevention study
Lenacapavir, a bi-annual injectable treatment for HIV prevention (PrEP), is being celebrated as a major advancement in the field following new study results showing a 96% reduction in HIV cases.